Genmab A/S (OTCMKTS:GNMSF – Get Rating) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 10,900 shares, a decline of 71.7% from the August 31st total of 38,500 shares. Based on an average daily volume of 1,400 shares, the short-interest ratio is currently 7.8 days.
Genmab A/S Price Performance
Shares of Genmab A/S stock traded up $10.50 during trading on Wednesday, hitting $324.00. 822 shares of the stock were exchanged, compared to its average volume of 1,136. The stock has a market cap of $21.18 billion, a price-to-earnings ratio of 34.99 and a beta of 0.77. The firm's 50-day moving average price is $352.46 and its 200 day moving average price is $336.97. Genmab A/S has a 12-month low of $260.25 and a 12-month high of $479.99.
Get Genmab A/S alerts:Genmab A/S (OTCMKTS:GNMSF – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $452.87 million during the quarter. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%.
About Genmab A/S
(Get Rating)Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Get a free copy of the StockNews.com research report on Genmab A/S (GNMSF)
- Can United Natural Foods Fight Both Inflation and the Fed?
- Mullen Automotive Is Ready To Get In Gear
- Cracker Barrel: A Tasty Treat Or Bad Apple?
- Defensive Stocks For A Volatile Market
- Will UPS Be Next to Deliver a Warning?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.